Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 24, Number 8—August 2018
Research

Toxoplasmosis in Transplant Recipients, Europe, 2010–2014

Florence Robert-Gangneux1Comments to Author , Valeria Meroni1, Damien Dupont, Françoise Botterel, José M. Aguado Garcia2, Marie-Pierre Brenier-Pinchart, Isabelle Accoceberry, Hamdi Akan2, Isabella Abbate, Katia Boggian, Fabrizio Bruschi2, Jordi Carratalà2, Miruna David2, Lubos Drgona2, Olgica Djurković-Djaković, Maria Carmen Farinas, Francesca Genco, Effrossyni Gkrania-Klotsas2, Andreas H. Groll2, Edward Guy, Cédric Hirzel, Nina Khanna, Özgür Kurt1, Lia Monica Junie1, Tiziana Lazzarotto, Oscar Len2, Nicolas J. Mueller, Patricia Munoz2, Zoi Dorothea Pana2, Emmanuel Roilides2, Tijana Stajner, Christian van Delden, Isabelle Villena1, Hervé Pelloux1, and Oriol Manuel2
Author affiliations: Université Rennes, Rennes, France (F. Robert-Gangneux); Centre Hospitalier Universitaire de Rennes, Rennes (F. Robert-Gangneux); European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland (V. Meroni, J.M. Aguado Garcia, F. Bruschi, J. Carratalà, M. David, L. Drgona, E. Gkrania-Klotsas, A.H. Groll, Ö. Kurt, L.M. Junie, O. Len, P. Munoz, Z.D. Pana, E. Roilides, I. Villena, H. Pelloux, O. Manuel); University of Pavia, Pavia, Italy (V. Meroni, F. Genco); Hôpital de la Croix-Rousse, Lyon, France (D. Dupont); Université Claude Bernard Lyon, Lyon (D. Dupont); Centre Hospitalier Universitaire Henri Mondor, Creteil, France (F. Botterel); University Hospital 12 de Octubre Universidad Complutense, Madrid, Spain (J.M. Aguado Garcia, H. Akan); Centre Hospitalier Universitaire Grenoble-Alpes, Grenoble, France (M.-P. Brenier-Pinchart); Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France (I. Accoceberry); Ankara University Cebeci Hospital, Ankara, Turkey (H. Akan); Lazzaro Spallanzani National Institute for Infectious Diseases, Rome, Italy (I. Abbate); St. Gallen Cantonal Hospital, St. Gallen, Switzerland (K. Boggian); Pisa University, Pisa, Italy (F. Bruschi); Bellvitge University Hospital-IDIBELL University of Barcelona, Barcelona, Spain (J. Carratalà); Queen Elizabeth Hospital, Birmingham, UK (M. David); Comenius University, Bratislava, Slovakia (L. Drgona); National Cancer Institute, Bratislava (L. Drgona); University of Belgrade, Belgrade, Serbia (O. Djurković-Djaković, T. Stajner); Hospital Universitario Marques de Valdecilla, Santander, Spain (M.C. Farinas); University of Cantabria, Santander (M.C. Farinas); Addenbrooke’s Hospital, Cambridge, UK (E. Gkrania-Klotsas); University Children’s Hospital Münster, Münster, Germany (A.H. Groll); Singleton Hospital, Swansea, Wales, UK (E. Guy); Bern University Hospital, Bern, Switzerland (C. Hirzel); University of Bern, Bern (C. Hirzel); Universitätsspital, Basel (N. Khanna); Acibadem Mehmet Ali Aydinlar, Istanbul, Turkey (Ö. Kurt); University of Medicine and Pharmacy Iuliu Hatieganu, Cluj Napoca, Romania (L.M. Junie); St. Orsola-Malpighi General Hospital, Bologna, Italy (T. Lazzarotto); University of Bologna, Bologna (T. Lazzarotto); Hospital Universitari Vall d’Hebron, Barcelona (O. Len); Zurich University Hospital, Zurich, Switzerland (N.J. Mueller); University of Zurich, Zurich (N.J. Mueller); Hospital General Gregorio Maranon, Madrid, Spain (P. Munoz); Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece (Z.D. Pana, E. Roilides); University Hospitals Geneva, Geneva, Switzerland (C. van Delden); Centre Hospitalier Universitaire de Reims, Reims, France (I. Villena); University Hospital, Lausanne, Switzerland (O. Manuel); University of Lausanne, Lausanne (O. Manuel)

Main Article

Table 3

Toxoplasmosis occurrence and outcomes for HSCT and SOT patients, according to prophylaxis, Europe, 2010–2014*

Characteristic HSCT, no. (%), n = 58† SOT, no. (%), n = 29‡ p value
Seropositive before transplantation 41/46 (89)§ 4/24 (17)¶ <0.0001
Diagnosis during chemoprophylaxis 9/50 (18) 5/28 (18) NS
Diagnosis after chemoprophylaxis
9/50 (18)
8/28 (29)
NS
2-mo survival rate
With prophylaxis 13/18 (72) 17/17 (100) <0.05
Without prophylaxis
18/32 (56)
9/11 (82)
0.1657
6-mo survival rate
With prophylaxis 9/18 (50) 17/17 (100) 0.01
Without prophylaxis 9/32 (28) 7/11 (64)# 0.0679

*HSCT, hematopoietic stem cell transplant; NS, not significant; SOT, solid organ transplant.
†Prophylaxiis data missing for 8 patients.
‡Prophylaxis data missing for 1 patient; incomplete information regarding dates of onset and/or stop of cotrimoxazole for 4 patients.
§Serology data missing data for 4 patients.
¶Serology data missing data for 4 patients.
#p<0.05 between SOT with or without chemoprophylaxis.

Main Article

1These authors are members of the Study Group for Clinical Parasitology of the European Society of Clinical Microbiology and Infectious Diseases.

2These authors are members of the Study Group for Infections in Compromised Hosts of the European Society of Clinical Microbiology and Infectious Diseases.

Page created: July 18, 2018
Page updated: July 18, 2018
Page reviewed: July 18, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external